D6M.F GENEDRIVE PLC LS -015

Healthcare Biotechnology Frankfurt Exchange
0.0123 EUR
Close of Oct 8, 2026
0.0060 0.0225
Market cap
EUR 19.8M
P/E
-
P/B
0.44x
ROE
-363.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2025.

Is D6M.F undervalued?

Graham number

The Graham number of GENEDRIVE PLC LS -015 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GENEDRIVE PLC LS -015 fundamental analysis

No fundamental analysis for GENEDRIVE PLC LS -015 yet.

GENEDRIVE PLC LS -015 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GENEDRIVE PLC LS -015

genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides Genedrive system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a certified test for identification of …

Full company profile